We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Imaging Tech to Improve Diagnosis and Treatment of Skin Cancers

By LabMedica International staff writers
Posted on 17 Oct 2025

Skin cancer is the most common malignancy worldwide, and accurately assessing tumor invasion or treatment response remains a major clinical challenge. More...

Current imaging methods, such as confocal microscopy and optical coherence tomography, provide high-resolution images only at shallow tissue depths, while deeper imaging approaches like ultrasound often lack contrast or precision. Now, a new non-invasive optical imaging method promises to overcome these limitations by providing deeper, clearer views of biological tissues.

The technology, being developed by researchers at the University of Arizona (Tucson, AZ, USA), is termed Synthetic Wavelength Imaging (SWI) and uses two distinct illumination wavelengths to generate a virtual “synthetic” wavelength. This longer wavelength allows light to penetrate deeper into tissue with minimal scattering while retaining the high contrast from the original wavelengths, enabling detailed visualization of skin cancers.

The project is specifically focusing on nonmelanoma skin cancers such as basal cell and squamous cell carcinoma, which present varied lesion depths and invasion patterns. If successful, the SWI method will provide the tunable imaging capabilities necessary to accurately assess tumor characteristics and monitor treatment. The researchers aim to translate these imaging advances into clinical practice to better define tumor margins and monitor treatment progress in real time.

The improved visualization may help detect invasive lesions earlier and personalize non-invasive therapy plans. In addition to skin cancer, the wide tunability of the synthetic wavelength could enable imaging of other tissues such as the breast or human brain, expanding its potential to other diagnostic and surgical applications.

"Our goal is to translate these imaging advances into clinical practice," said Curiel-Lewandrowski, principal investigator. "If we can detect invasive lesions earlier, define tumor margins more precisely, and monitor response to non-invasive treatments in real time, we can maximize the effectiveness of emerging therapeutic approaches. This will also allow us to tailor intervention length and dosing individually to each patient."

Related Links:
University of Arizona


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
New
Multi-Chamber Washer-Disinfector
WD 390
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The findings point to the feasibility of a quick, noninvasive urine-based approach to support earlier decision-making in multiple psychiatric conditions (photo credit: Shutterstock)

Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders

Delays in diagnosing serious psychiatric conditions can leave patients without timely support and complicate treatment planning. For bipolar disorder, average time to diagnosis can exceed nine years, and... Read more

Molecular Diagnostics

view channel
Image: The schematic diagram links key MASLD, MASH, and MASLD-HCC molecular drivers to emerging multi‑omics biomarkers and therapeutic modalities, highlighting the current barriers in clinical translation and strategic solutions aimed at refined risk stratification and personalized medicine (Photo courtesy of ©Science China Press)

Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.